Gastric Parietal Cell IgG Serum

Gastric Parietal Cell IgG Serum is offered at the Immunopathology laboratory at the main campus.

The new test is a FDA-approved semi-quantitative assay to be used as an aid in diagnosing autoimmune gastritis and pernicious anemia. The numerical values (ELISA units) are only reported for informational purposes and may not correlate with presence of clinically overt disease or disease severity. The new assay targets purified gastric parietal cell H^+/K^+ ATPase which is the main target in autoimmune gastritis.

This test offers improved sensitivity and specificity compared with the IFA. Gastric parietal cell IgG may be present years before clinical manifestations and complications such as pernicious anemia. The seroprevalence increases with age and has been reported in 2% of normal population younger than 20 years and in 16% of population older than 60 years; this is particularly the case in those with concomitant Hashimoto thyroiditis, Sjögren's syndrome, and concomitant *Helicobacter pylori* infection, among other conditions, therefore, clinical correlation is highly recommended.

Test Overview

Test Name	Gastric Parietal Cell IgG Serum
Ordering Mnemonic	PARIES
Methodology	Enzyme-linked immunosorbent assay (ELISA) (aka EIA)
Specimen Requirements	Primary container SST (Gold) 1.0 mL; Minimum 0.3 mL
Stability	After separation from cells: 24 hours (Ambient), 7 days (Refrigerated), 14 days (frozen ≤ -20°C)
Clinical Information	As an aid in diagnosing autoimmune gastritis
Reference Range	Negative; ≤20
CPT Code	83516
Days Performed	Tuesday, Friday

Technical Information Contact:

Matthew Dee, C(ASCP)
Supervisor, Immunopathology
216.445.0511

Clinical Information Contact:

Kamran Kadkhoda, PhD, D (ABMM), D(ABMLI)
Medical Director, Immunopathology Laboratory
kadkhok@ccf.org

202211.004